Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.